Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CC-90010 + Temozolomide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CC-90010 | CC 90010|CC90010|BMS-986378|BMS 986378|BMS986378 | BET Inhibitor (Pan) 32 | CC-90010 is a reversible, small molecule drug that binds to BD2 (bromodomain 2) of BET proteins and inhibits interaction with acetylated histones, potentially resulting in disrupted expression of genes that promote cell growth, and inhibition of proliferation of tumor cells overexpressing BET proteins (PMID: 32240793). | |
Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04324840 | Phase Ib/II | CC-90010 + Temozolomide | A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Subjects With Newly Diagnosed Glioblastoma | Terminated | USA | SWE | NOR | NLD | ITA | ESP | DNK | 0 |